| 000 | 01762 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516144458.0 | ||
| 264 | 0 | _c20130801 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1432-0851 | ||
| 024 | 7 |
_a10.1007/s00262-013-1420-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPatel, Sandip Pravin | |
| 245 | 0 | 0 |
_aAnti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. _h[electronic resource] |
| 260 |
_bCancer immunology, immunotherapy : CII _cJun 2013 |
||
| 300 |
_a1011-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
| 650 | 0 | 4 |
_aAntibody-Dependent Cell Cytotoxicity _ximmunology |
| 650 | 0 | 4 |
_aAntigens, Neoplasm _ximmunology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _ximmunology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMucin 5AC _ximmunology |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Binding _ximmunology |
| 650 | 0 | 4 | _aRecombinant Fusion Proteins |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aBristol, Andrew | |
| 700 | 1 | _aSaric, Olga | |
| 700 | 1 | _aWang, Xue-Ping | |
| 700 | 1 | _aDubeykovskiy, Alex | |
| 700 | 1 | _aArlen, Philip M | |
| 700 | 1 | _aMorse, Michael A | |
| 773 | 0 |
_tCancer immunology, immunotherapy : CII _gvol. 62 _gno. 6 _gp. 1011-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00262-013-1420-z _zAvailable from publisher's website |
| 999 |
_c22675010 _d22675010 |
||